Th2 Cytokines IL-4, IL-13, and IL-10 Promote Differentiation of Pro-Lymphatic Progenitors Derived from Bone Marrow Myeloid Precursors.
Th2 cytokines
lymphangiogenesis
lymphatic endothelial progenitors
myeloid cell differentiation
Journal
Stem cells and development
ISSN: 1557-8534
Titre abrégé: Stem Cells Dev
Pays: United States
ID NLM: 101197107
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
pubmed:
21
4
2022
medline:
14
6
2022
entrez:
20
4
2022
Statut:
ppublish
Résumé
Myeloid-lymphatic endothelial cell progenitors (M-LECP) are a subset of bone marrow (BM)-derived cells characterized by expression of M2-type macrophage markers. We previously showed significant contribution of M-LECP to tumor lymphatic formation and metastasis in human clinical breast tumors and corresponding mouse models. Since M2 type is induced in macrophages by immunosuppressive Th2 cytokines IL-4, IL-13, and IL-10, we hypothesized that these factors might promote pro-lymphatic specification of M-LECP during their differentiation from BM myeloid precursors. To test this hypothesis, we analyzed expression of Th2 cytokines and their receptors in mouse BM cells under conditions leading to M-LECP differentiation, namely, CSF-1 treatment followed by activation of TLR4. We found that under these conditions, all three Th2 receptors were strongly upregulated in >95% of the cells that also secrete endogenous IL-10, but not IL-4 or IL-13 ligands. However, addition of any of the Th2 factors to CSF-1 primed cells significantly increased generation of myeloid-lymphatic progenitors as indicated by co-induction of lymphatic-specific (eg, Lyve-1, integrin-a9, collectin-12, and stabilin-1) and M2-type markers (eg, CD163, CD204, CD206, and PD-L1). Antibody-mediated blockade of either IL-10 receptor (IL-10R) or IL-10 ligand significantly reduced both immunosuppressive and lymphatic phenotypes. Moreover, tumor-recruited Lyve-1
Identifiants
pubmed: 35442077
doi: 10.1089/scd.2022.0004
pmc: PMC9232236
doi:
Substances chimiques
Cytokines
0
Interleukin-13
0
Ligands
0
Interleukin-10
130068-27-8
Interleukin-4
207137-56-2
Macrophage Colony-Stimulating Factor
81627-83-0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
322-333Subventions
Organisme : NCI NIH HHS
ID : R01 CA199649
Pays : United States
Références
Blood. 2011 Oct 13;118(15):4199-208
pubmed: 21846901
EMBO J. 2002 Apr 2;21(7):1505-13
pubmed: 11927535
Growth Factors. 2002 Jun;20(2):99-107
pubmed: 12148568
Rep Biochem Mol Biol. 2018 Oct;7(1):30-37
pubmed: 30324115
Lab Invest. 2013 Jul;93(7):844-54
pubmed: 23752129
Microcirculation. 2008 Jan;15(1):49-64
pubmed: 17952801
Breast Cancer Res Treat. 2012 May;133(1):11-21
pubmed: 22057973
Front Oncol. 2019 Mar 26;9:187
pubmed: 30972297
Nat Med. 2011 Nov 07;17(11):1371-80
pubmed: 22064427
Angiogenesis. 2014 Apr;17(2):373-81
pubmed: 24449091
Semin Immunol. 2015 Aug;27(4):237-48
pubmed: 26561250
Invest Ophthalmol Vis Sci. 2007 May;48(5):2162-71
pubmed: 17460275
Cells. 2019 Dec 15;8(12):
pubmed: 31847487
Clin Exp Metastasis. 2015 Dec;32(8):847-56
pubmed: 26385103
J Pathol. 2013 Jan;229(2):176-85
pubmed: 23096265
Scand J Immunol. 2014 May;79(5):305-14
pubmed: 24521472
J Pathol. 2006 May;209(1):67-77
pubmed: 16482496
Cancer Res. 2001 Mar 1;61(5):1786-90
pubmed: 11280723
J Leukoc Biol. 2017 Aug;102(2):253-263
pubmed: 28408396
Am J Pathol. 2016 Jan;186(1):159-71
pubmed: 26608451
Cell Cycle. 2010 Dec 15;9(24):4824-35
pubmed: 21150330
PLoS One. 2013 Sep 10;8(9):e74293
pubmed: 24058540
Sci Rep. 2017 Sep 12;7(1):11315
pubmed: 28900244
PLoS One. 2015 Oct 06;10(10):e0139598
pubmed: 26440936
Wiley Interdiscip Rev Syst Biol Med. 2013 Jan-Feb;5(1):111-24
pubmed: 23209022
Adv Exp Med Biol. 2020;1234:87-105
pubmed: 32040857
Front Oncol. 2019 May 31;9:456
pubmed: 31214501
Annu Rev Physiol. 2019 Feb 10;81:535-560
pubmed: 30742781
Biochim Biophys Acta. 2011 Feb;1813(2):308-14
pubmed: 21167870
PLoS One. 2017 Jun 9;12(6):e0179257
pubmed: 28598999
Blood. 1996 Oct 1;88(7):2549-58
pubmed: 8839847
Cytokine Growth Factor Rev. 2016 Dec;32:3-15
pubmed: 27165851
J Leukoc Biol. 2006 Oct;80(4):862-9
pubmed: 16895973
Front Biosci (Landmark Ed). 2011 Jan 01;16(2):723-39
pubmed: 21196198
Microvasc Res. 2014 Nov;96:10-5
pubmed: 25132472
Cancer Res. 2012 Dec 15;72(24):6338-43
pubmed: 23222300
Histol Histopathol. 2018 Feb;33(2):133-145
pubmed: 28681373
J Cell Biochem. 2009 May 1;107(1):134-43
pubmed: 19241443
Mol Biol Cell. 2007 Apr;18(4):1421-9
pubmed: 17287396
J Surg Res. 2011 May 15;167(2):e211-9
pubmed: 19765725
Am J Pathol. 2019 Nov;189(11):2269-2292
pubmed: 31421071
J Cancer Res Clin Oncol. 2010 Jan;136(1):35-45
pubmed: 19572148
Microcirculation. 2012 Oct;19(7):567-79
pubmed: 22574929
Immunol Res. 2012 Sep;53(1-3):11-24
pubmed: 22418728
Nature. 2013 May 9;497(7448):239-43
pubmed: 23575636
PLoS One. 2012;7(3):e31794
pubmed: 22396739
J Cell Biol. 1999 Feb 22;144(4):789-801
pubmed: 10037799
Blood. 2009 Aug 27;114(9):1764-7
pubmed: 19564635
Pathophysiology. 2010 Sep;17(4):229-51
pubmed: 20036110
Cancer Immunol Immunother. 2017 Nov;66(11):1485-1496
pubmed: 28733709
Biochem Biophys Res Commun. 2013 May 10;434(3):600-5
pubmed: 23583403
Pol Przegl Chir. 2013 Dec;85(12):714-20
pubmed: 24468592
Pathol Int. 2016 Feb;66(2):83-93
pubmed: 26778807
J Clin Invest. 2012 Mar;122(3):787-95
pubmed: 22378047
J Immunol. 2005 Mar 15;174(6):3484-92
pubmed: 15749884
Int J Cancer. 2011 Jul 1;129(1):122-32
pubmed: 20824698
J Immunol. 2012 Apr 1;188(7):3160-8
pubmed: 22371397
J Bone Miner Res. 2010 Aug;25(8):1701-6
pubmed: 20572008
Breast Cancer Res. 2012 May 22;14(3):R81
pubmed: 22616919
Cell. 2008 Jan 25;132(2):259-72
pubmed: 18243101
Arthritis Rheum. 2009 Sep;60(9):2666-76
pubmed: 19714652
Int J Dev Biol. 2011;55(7-9):861-7
pubmed: 22161841
Blood. 2004 Dec 15;104(13):3849-57
pubmed: 15297319
Annu Rev Immunol. 2013;31:317-43
pubmed: 23298208
Immunobiology. 2012 Dec;217(12):1301-14
pubmed: 22954708
Cytokine. 2000 Sep;12(9):1312-21
pubmed: 10975989